Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Free Report) saw a significant drop in short interest in October. As of October 30th, there was short interest totaling 184,372 shares, a drop of 77.5% from the October 15th total of 818,602 shares. Approximately 6.6% of the company’s shares are short sold. Based on an average daily volume of 7,649,526 shares, the days-to-cover ratio is presently 0.0 days.
Alaunos Therapeutics Price Performance
TCRT stock traded up $0.01 during trading hours on Friday, reaching $1.63. 17,342 shares of the stock were exchanged, compared to its average volume of 2,219,019. The firm’s 50-day moving average is $1.64 and its 200-day moving average is $2.28. The company has a market cap of $5.40 million, a price-to-earnings ratio of -0.85 and a beta of -1.02. Alaunos Therapeutics has a 12 month low of $0.72 and a 12 month high of $4.50.
Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.41) earnings per share (EPS) for the quarter.
Analyst Ratings Changes
TCRT has been the subject of a number of recent analyst reports. Weiss Ratings cut shares of Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 17th. TD Cowen assumed coverage on Alaunos Therapeutics in a report on Friday. They set a “buy” rating on the stock. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold”.
Check Out Our Latest Analysis on Alaunos Therapeutics
About Alaunos Therapeutics
Alaunos Therapeutics, Inc. is a biotechnology company focused on developing genetically engineered T-cell therapies for cancer. The company has concentrated on T-cell receptor (TCR) therapies designed to recognize and attack tumor-specific mutations, with an emphasis on treating solid tumors that can be difficult to address with conventional immunotherapies. The company’s research platform has included the Sleeping Beauty gene-transfer system, a nonviral technology intended to introduce therapeutic T-cell receptors into a patient’s own T cells.
See Also
- Five stocks we like better than Alaunos Therapeutics
- Is Buying the NVIDIA Dip a Mistake? 3 Value Stocks Offer a Different Path Forward
- Costco’s Record $30 Dividend Shows Just How Strong Its Cash Machine Is
- Heavy Lifting: Can USA Rare Earth Turn Its First Sales Into Big Profits?
- These 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
